文献速递瓣膜外科

19 mm生物瓣行主动脉瓣置换术的长期结局

Long-term outcomes after aortic valve replacement using a 19-mm bioprosthesis.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

本研究纳入2008至2012年在本院连续接受19 mm生物瓣主动脉瓣置换术(SAVR)的132例患者,中位随访7.7年。结果显示5年和10年总体生存率分别为79.4%和52.9%,5年和10年免于主要瓣膜相关不良事件率分别为89.6%和74.2%;中度或重度患者-人工瓣膜不匹配(PPM)均与晚期死亡、主要瓣膜相关不良事件或心力衰竭无关。随访超声显示左心室射血分数显著升高、平均跨瓣压差和左心室质量下降。

要点

  • 19 mm生物瓣SAVR的10年生存率为52.9%,免于主要瓣膜相关不良事件率为74.2%。
  • 中度及重度PPM分别占27.3%和5.3%,均未与晚期死亡或主要瓣膜相关不良事件相关。
  • 随访超声显示左心室射血分数升高、跨瓣压差和左心室质量下降。

核心结论

  • 19 mm生物瓣行SAVR可获得满意的长期临床与血流动力学结局。

研究设计与样本

  • 单中心连续病例系列,纳入2008至2012年接受19 mm生物瓣SAVR的患者,共132例,中位随访7.7年。

主要发现

  • 5年和10年总体生存率分别为79.4%和52.9%。
  • 5年和10年免于主要瓣膜相关不良事件率分别为89.6%和74.2%。
  • 中度PPM 36例(27.3%)、重度PPM 7例(5.3%),均与晚期死亡、主要瓣膜相关不良事件或心力衰竭无关。
  • 随访超声(中位间隔4.8年,覆盖术后存活≥6个月患者的80%)显示左心室射血分数显著升高、平均跨瓣压差下降、左心室质量下降。
  • 随访中17例出现中度或重度血流动力学结构性瓣膜退化,但未影响晚期生存、免于主要瓣膜相关不良事件率或心力衰竭。

临床怎么用

  • 对于主动脉瓣环较小的主动脉瓣狭窄患者,19 mm生物瓣SAVR可作为长期结局可接受的选项。
  • 术后中度或重度PPM的出现不必然预示晚期不良事件,但仍需结合超声随访评估血流动力学。

局限性

  • 单中心回顾性连续病例系列,样本量132例,随访超声仅在部分患者中获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transcatheter aortic valve replacement is known to be associated with improved haemodynamics in patients with aortic stenosis and a small aortic annulus. However, limited benchmark data are available regarding the long-term outcomes in patients treated with surgical aortic valve replacement (SAVR). We investigated the long-term outcomes of SAVR using a 19-mm bioprosthesis. METHODS: This study included consecutive patients who underwent SAVR using a 19-mm bioprosthesis at our hospital between 2008 and 2012. RESULTS: In a total of 132 patients, moderate and severe prosthesis-patient mismatch occurred in 36 (27.3%) and 7 patients (5.3%), respectively. The median follow-up period was 7.7 years. The overall 5- and 10-year survival rates were 79.4% and 52.9%, respectively. The 5- and 10-year freedom from major adverse valve-related events rates were 89.6% and 74.2%, respectively. Neither moderate nor severe prosthesis-patient mismatch was associated with late mortality, major adverse valve-related events or heart failure. Follow-up echocardiographic data were obtained at a median interval of 4.8 years in 80% of patients who survived ≥6 months postoperatively. Follow-up echocardiographic data showed a significantly increased left ventricular ejection fraction, decreased mean transvalvular/transprosthetic pressure gradients and a decreased mean left ventricular mass. At follow-up, we observed moderate or severe haemodynamic structural valve deterioration in 17 patients; however, structural valve deterioration did not affect late survival or freedom from major adverse valve-related events rates, or heart failure. CONCLUSIONS: SAVR using the 19-mm bioprosthesis was associated with satisfactory long-term clinical and haemodynamic outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Okamura H, Kusadokoro S, Mieno M, et al. Long-term outcomes after aortic valve replacement using a 19-mm bioprosthesis. Eur J Cardiothorac Surg. 2022. PMID: 34431991. doi:10.1093/ejcts/ezab379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。